160 related articles for article (PubMed ID: 37541902)
1. Efficacy and safety of bortezomib plus dexamethasone in patients with refractory primary immune thrombocytopenia: A single-center study.
Liu LN; Cui YS; Fang BJ
Asian J Surg; 2023 Dec; 46(12):5482-5483. PubMed ID: 37541902
[No Abstract] [Full Text] [Related]
2. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Binlich F; Richardson PG
Lancet Haematol; 2016 Nov; 3(11):e506-e515. PubMed ID: 27751707
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
4. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
[TBL] [Abstract][Full Text] [Related]
6. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
[TBL] [Abstract][Full Text] [Related]
7. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Iida S; Wakabayashi M; Tsukasaki K; Miyamoto K; Maruyama D; Yamamoto K; Takatsuka Y; Kusumoto S; Kuroda J; Ando K; Kikukawa Y; Masaki Y; Kobayashi M; Hanamura I; Asai H; Nagai H; Shimada K; Tsukamoto N; Inoue Y; Tobinai K
Cancer Sci; 2018 May; 109(5):1552-1561. PubMed ID: 29478257
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Chari A; Htut M; Zonder JA; Fay JW; Jakubowiak AJ; Levy JB; Lau K; Burt SM; Tunquist BJ; Hilder BW; Rush SA; Walker DH; Ptaszynski M; Kaufman JL
Cancer; 2016 Nov; 122(21):3327-3335. PubMed ID: 27433944
[TBL] [Abstract][Full Text] [Related]
11. Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma.
Suzuki K; Sunami K; Matsumoto M; Maki A; Shimada F; Suzuki K; Shimizu K
Acta Haematol; 2021; 144(3):264-274. PubMed ID: 33279887
[TBL] [Abstract][Full Text] [Related]
12. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
[TBL] [Abstract][Full Text] [Related]
13. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Moreau P; Chanan-Khan A; Roberts AW; Agarwal AB; Facon T; Kumar S; Touzeau C; Punnoose EA; Cordero J; Munasinghe W; Jia J; Salem AH; Freise KJ; Leverson JD; Enschede SH; Ross JA; Maciag PC; Verdugo M; Harrison SJ
Blood; 2017 Nov; 130(22):2392-2400. PubMed ID: 28847998
[TBL] [Abstract][Full Text] [Related]
14. A Three-Drug Combo for Multiple Myeloma.
Cancer Discov; 2016 Nov; 6(11):OF4. PubMed ID: 27630127
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Kumar SK; Harrison SJ; Cavo M; de la Rubia J; Popat R; Gasparetto C; Hungria V; Salwender H; Suzuki K; Kim I; Punnoose EA; Hong WJ; Freise KJ; Yang X; Sood A; Jalaluddin M; Ross JA; Ward JE; Maciag PC; Moreau P
Lancet Oncol; 2020 Dec; 21(12):1630-1642. PubMed ID: 33129376
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
Iida S; Ichinohe T; Shinagawa A; Suzuki K; Takezako N; Aoki M
Int J Hematol; 2018 Apr; 107(4):460-467. PubMed ID: 29260507
[TBL] [Abstract][Full Text] [Related]
17. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.
Lu J; Fu W; Li W; Hu J; An G; Wang Y; Fu C; Chen L; Jin J; Cen X; Ge Z; Cai Z; Niu T; Qi M; Sun S; Gai X; Liu W; Liu W; Yang X; Huang X
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e699-e709. PubMed ID: 34108127
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab plus bortezomib and dexamethasone
Spencer A; Lentzsch S; Weisel K; Avet-Loiseau H; Mark TM; Spicka I; Masszi T; Lauri B; Levin MD; Bosi A; Hungria V; Cavo M; Lee JJ; Nooka AK; Quach H; Lee C; Barreto W; Corradini P; Min CK; Scott EC; Chanan-Khan AA; Horvath N; Capra M; Beksac M; Ovilla R; Jo JC; Shin HJ; Sonneveld P; Soong D; Casneuf T; Chiu C; Amin H; Qi M; Thiyagarajah P; Sasser AK; Schecter JM; Mateos MV
Haematologica; 2018 Dec; 103(12):2079-2087. PubMed ID: 30237264
[TBL] [Abstract][Full Text] [Related]
20. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
